Cell line · CVCL_2574
LIM1215
Cancer cell line, Homo sapiens. Colon adenocarcinoma. 30 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. LIM1215. Cell lines, record CVCL_2574. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_2574
On this page
Cell line
As Cellosaurus gives it.
- Name
- LIM1215
- Accession
- CVCL_2574
- RRID
- RRID:CVCL_2574
- Synonyms
- Lim1215, LIM 1215, LIM-1215
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 34Y
- Category
- Cancer cell line
- Diseases
- Colon adenocarcinoma (NCIt C4349); Lynch syndrome (NCIt C8494); Lynch syndrome (ORDO Orphanet_144)
- Derived from
- Omentum (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers30
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| High TMEM161A expression drives malignant phenotypes and predicts poor prognosis in colorectal cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39605519 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 30
See all 30 papersRelatives15
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | LIM1215 IR | CVCL_E7AP | Cell lines | |
| Derived from it | LIM1215 KRAS (G12A/+) | CVCL_LC77 | Cell lines | |
| Derived from it | LIM1215 KRAS (G12C/+) | CVCL_LC81 | Cell lines | |
| Derived from it | LIM1215 KRAS (G12D/+) | CVCL_LC80 | Cell lines | |
| Derived from it | LIM1215 KRAS (G12R/+) | CVCL_LC76 | Cell lines | |
| Derived from it | LIM1215 KRAS (G12S/+) | CVCL_LC78 | Cell lines | |
| Derived from it | LIM1215 KRAS (G12V/+) | CVCL_LC79 | Cell lines | |
| Derived from it | LIM1215 KRAS (G13D/+) | CVCL_LC82 | Cell lines | |
| Derived from it | LIM1215 PIK3CA (E545K/+) | CVCL_A4IH | Cell lines | |
| Derived from it | LIM1215 PIK3CA (H1047R/+) | CVCL_A4IG | Cell lines |
1 to 10 of 15
See all 15 relativesCell banks2
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2574
GET https://conductscience.org/api/cell-lines/v1/CVCL_2574/papers?page=2